# Vortioxetine to Prevent Return of Symptoms in Children With Depression

> **NCT05014919** · PHASE3 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 35 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05014919
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-10
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-04-28
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** The study was terminated based on new efficacy data from another study.
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014919, "Vortioxetine to Prevent Return of Symptoms in Children With Depression". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05014919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*